Invuity is counting on the fact that open surgeries, in which a sizable incision is made and the operation is illuminated only from above, are on their way out. Instead, the company is targeting the growing number of surgical procedures that may not be endoscopic or minimally invasive--but are a bit of a hybrid, open surgeries with smaller incisions and traditional medical instruments.
Last June, Auxogyn's Eeva System was the first to be cleared by FDA to aid in IVF embryo selection in combination with traditional morphology. Now the startup has raised $34.3 million, out of a planned $41 million, financing round to start commercializing this test, according to an SEC filing.
Minimally invasive surgery is here to stay as patients enjoy briefer recovery times--and payers benefit from lower associated costs. But as the incisions get smaller, visualization gets tougher. That's where surgical photonics company Invuity steps in.
After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.
Kinsa made its smartphone plug-in thermometer, the first cleared by FDA, available at several major consumer retailers including Apple and Amazon earlier this month. Now, in a move that's inverse to the usual order of events for med tech startups, the company has raised a $9.6 million Series A.
After taking the helm and pointing South San Francisco-based iPierian in a new direction, CEO Nancy Stagliano today unveiled a $30 million venture round designed to get her crew into the clinic with a lead antibody program, while a separate project is being spun out into a new biotech that she will also direct.
In the latest biotech business formed around a major drugmaker's assets, Atara Biotherapeutics has emerged with early-stage drug candidates against cancer and other serious diseases from biopharma behemoth Amgen.
San Diego-based Elcelyx Therapeutics is jumping out of stealth mode today with news that it has picked up an extended venture round, bringing its total venture backing to $20 million as the fledgling biotech pursues a new formulation of metformin as well as a dietary supplement.
This morning the biotech--which is backed by Google Ventures, Third Rock and Kleiner Perkins--announced that Novartis is expanding on their pact with plans to use the test to properly match patients to most of their Phase I and Phase II cancer trials over the next three years.
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.